News Drug Development The future of pain relief: Exploring opioid alternatives July 16, 2026 | 1 min read | Jennifer C. Smith-Parker, BioSpace Insights Twitter LinkedIn Facebook Email Print In this episode of Denatured, you’ll hear from Lance Alstodt, chairman and CEO at Biorestorative Therapies, and Paul Mieyal, chief business officer at South Rampart Pharma. We explore why pain has remained such a difficult therapeutic area to tackle and one of the biggest unmet needs today, and how non-opioid mechanisms to regenerative therapies could reshape the future of treatment. > Listen on Spotify> Listen on Apple Podcasts> Listen on Amazon Music> Listen on iHeartIn this episode of Denatured, you’ll listen to Lance Alstodt, chairman and CEO at Biorestorative Therapies, and Paul Mieyal, chief business officer at South Rampart Pharma. Pain remains one of medicine’s toughest challenges, with vast unmet need, and we look at why progress has been so slow — and how emerging approaches, from non‑opioid pathways to regenerative treatments, could fundamentally change the therapeutic landscape.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsLance Alstodt, Chairman & CEO, BioRestorative TherapiesPaul Mieyal, Chief Business Officer, South Rampart PharmaDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations. Twitter LinkedIn Facebook Email Print Podcasts Denatured Clinical research Drug discovery Pain Jennifer C. Smith-Parker Jennifer C. Smith-Parker is Director of Insights at BioSpace. She has been been immersed for 20 years in healthcare, first as a journalist and editor before pivoting to corporate, brand, and product communications. A skilled storyteller, she is adept at creating diverse content across platforms and crafting narratives that drive engagement, strengthen reputation, and deliver measurable growth. You can reach her at Jennifer.Smith-Parker@BioSpace.com. BioSpace Insights The BioSpace Insights teams performs research and analysis on industry trends for BioSpace and clients, producing industry reports, podcasts, events and articles.
biospace· 5d ago
saveThe future of pain relief: Exploring opioid alternatives
July 16, 2026read original ↗
In this episode of Denatured, you’ll hear from Lance Alstodt, chairman and CEO at Biorestorative Therapies, and Paul Mieyal, chief business officer at South Rampart Pharma. We explore why pain has remained such a difficult therapeutic area to tackle and one of the biggest unmet needs today, and how non-opioid mechanisms to regenerative therapies could reshape the future of treatment.
307 words · extracted 1d agoread original ↗
🔗 mentioned in this article
no entities indexed yet
comments(0)
5-min edit window · permanent after that